A Double Blind, Single Centric, Randomized, Placebo controlled study to demonstrate the efficacy and safety of Omshree Savier/ Omshreeraj (test products) compared to placebo to manage mild to moderate to severe symptoms of covid infections in subjects who are diagnosed as covid positive.

Omshree Sidha Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

研究概览

暂无简介。

•1. Adult patients between 18 years and 65 years old, both men or women.
•2. Subject with confirmed mild to moderate to severe COVID-19 in less than 5 days, preferably who has a history of Asthma, Pneumonia, Heart disease or Diabetic and who meets any of the following criteria:
•a. Respiratory distress, RR Ã¢â?°Â¥ 30 times/min
•b. In resting state, finger oxygen saturation (SpO2) Ã¢â?°Â¤93%
•c. X-ray of chest showing evidence of pulmonary infiltrates.
•3. The informed consent signed.
•4. Subjects willing to comply with the study Protocol.

•1. Creatinine level is less than 1.10.
•2. History of severe liver or kidney diseases.
•3. History of any malignancies.
•4. Subjects who are hypersensitive to herbal medications.
•5. Subjects who are participating in any other trial within 30 days prior to consent.
•6. Pregnant or lactating women.
•7. Any other circumstances that the investigator considers inappropriate for the participation in this study.
•8. Subjects who are unwilling to follow the study plan.
•9. Any condition which subject may have which can cause increase risk of bleeding.

发起方

Omshree Sidha Hospital